Back to top
more

Halozyme Therapeutics (HALO)

(Delayed Data from NSDQ)

$38.57 USD

38.57
547,082

+0.11 (0.29%)

Updated Apr 26, 2024 04:00 PM ET

After-Market: $38.55 -0.02 (-0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value B Growth B Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 30% (76 out of 252)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Brokerage Reports

Research for HALO

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

0 items in cart

Halozyme Therapeutics, Inc. [HALO]

Reports for Purchase

Showing records 141 - 160 ( 181 total )

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 141

08/10/2012

Industry Report

Pages: 7

Life Sciences MAC Best Ideas Conference

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 142

08/07/2012

Company Report

Pages: 8

Q2:12 Update - Buying Opportunity as rHuPH20 Concerns Overdone - Hylenex, Insulin and Roche Programs.

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 143

08/01/2012

Company Report

Pages: 7

Believe Sell-off Overdone - Concerns ONLY Related to Plasma-Derived Product Combos

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 144

07/31/2012

Industry Report

Pages: 42

August 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 100.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 145

07/02/2012

Industry Report

Pages: 40

July 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 146

06/10/2012

Daily Note

Pages: 7

ADA Data Confirms Hylenex Facilitates Tighter Glucose Control

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 147

06/05/2012

Industry Report

Pages: 40

June 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 148

06/01/2012

Industry Report

Pages: 5

The Week Ahead in Life Sciences - Upcoming Events for the Week of June 3

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 149

05/22/2012

Company Report

Pages: 7

BAX: FDAs BPAC Advisory Panel Meeting in July August is Probably a No Go The Bull and Bear Case for Baxters HyQ

Provider: COLLIERS SECURITIES

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 150

05/08/2012

Company Report

Pages: 6

Q2:12 Update - Insulin Pump Setting Data ADA June 8-12 to be Major Catalyst

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 151

04/16/2012

Company Report

Pages: 7

Believe Selloff Over Done - Positive Catalysts Ahead to Outweigh Potential Risks

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 152

04/12/2012

Industry Report

Pages: 5

LIFE SCIENCES -The Week Ahead in Life Sciences - Upcoming Events for the Week of April 15

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 153

04/05/2012

Industry Report

Pages: 5

LIFE SCIENCES: The Week Ahead in Life Sciences - Upcoming Events for the Week of April 8

Provider: WEDBUSH SECURITIES INC.

Analyst: MOUSSATOS L

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 154

03/25/2012

Daily Note

Pages: 5

Herceptin SC HannaH Study Results Positive - Reiterate OUTPERFORM and BEST IDEA

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 155

03/15/2012

Company Report

Pages: 4

Dropping Coverage

Provider: Roth Capital Partners, Inc.

Analyst: MARTIN J

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 156

03/12/2012

Company Report

Pages: 6

Q4 Update - More to Come - Reiterate OUTPERFORM and Best Ideas Recommendation

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 25.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 157

03/05/2012

Industry Report

Pages: 40

Biotechnology/Biopharmaceuticals/BioDefense: March 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 158

02/07/2012

Daily Note

Pages: 5

ViroPharma Manufacturing Setback Unlikely to Affect HALO Partnership - Commitment to SC Cinryze with HALO''s rHuPH20 a High Priority in 2012

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 159

02/01/2012

Daily Note

Pages: 5

Roche Annual Call Takeaways - Herceptin SC Phase III Data March - MabThera Data 2012; Reiterate OUTPERFORM

Provider: WEDBUSH SECURITIES INC.

Analyst: WADE G

Price: 10.00

Research Provided by a Third Party

Company: Halozyme Therapeutics, Inc.

Industry: Medical - Biomedical and Genetics

Record: 160

01/31/2012

Industry Report

Pages: 38

February 2012 Potential Catalysts & Milestones - Monthly Update

Provider: WEDBUSH SECURITIES INC.

Price: 75.00

Research Provided by a Third Party